Structural characterization and antitumor activity of platinum(II) complexes with phenothiazine and N-methylphenothiazine
Authors
Ašanin P., DarkoVojnović, Sandra
![](/themes/Mirageimagine/images/orcid.png)
Andrejević P., Tina
Marković R., Violeta
Perdih, Franc
![](/themes/Mirageimagine/images/orcid.png)
Turel, Iztok
![](/themes/Mirageimagine/images/orcid.png)
Djuran I., Miloš
Nikodinović-Runić, Jasmina
![](/themes/Mirageimagine/images/orcid.png)
Glišić Đ., Biljana
Conference object (Published version)
![](/themes/Mirageimagine//images/creativecommons/arr.png)
Metadata
Show full item recordAbstract
Cisplatin is one of the most used anticancer agents, and along with carboplatin and
oxaliplatin, is a part of more than 50% of clinically applied anticancer regimens [1]. However,
the side effects of cisplatin are severe and include dose-limiting toxicity, such as neurotoxicity,
nephrotoxicity and ototoxicity. Platinum(II) complexes with different structure from cisplatin
provide many opportunities for design of novel antitumor drugs with improved
pharmacological properties. Considering this, in the present study, new platinum(II) complexes
with phenothiazine (phtz) and N-methylphenothiazine (N-Mephtz), [PtCl2(phtz)(CH3CN)] (1)
and [PtCl2(N-Mephtz)(CH3CN)] (2), were synthesized. These complexes were characterized by
elemental microanalysis, NMR (1H and 13C) and IR spectroscopic measurements, while the
structure of complex 1 was determined by single-crystal X-ray diffraction analysis. The
antitumor activity of the platinum(II) complexes was tested in vitro against a panel of h...uman
cancer cell lines, including A549 (lung cancer), A375 (melanoma, skin cancer), MDA-MB-231
(breast cancer), and HCT116 (colon cancer). To check the selectivity of the synthesized
complexes 1 and 2, a healthy MRC-5 cell line (lung fibroblasts) was also included in this study.
Keywords:
anticancer activity / platinum(II) complexes / cisplatin / antitumor drug / cytotoxicitySource:
16th International Symposium on Applied Bioinorganic Chemistry, 2023, 195-Publisher:
- Greece : University of Ioannina
Funding / projects:
- This research was supported by the Science Fund of the Republic of Serbia, Grant No. 7730810, Valueadded biologics through eco-sustainable routes – BioECOLogics and by the Slovenian Research Agency (grant P1-0175).
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia, institutional funding - 200042 (University of Belgrade, Institute of Molecular Genetics and Genetic Engineering) (RS-MESTD-inst-2020-200042)
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia, institutional funding - 200122 (University of Kragujevac, Faculty of Science) (RS-MESTD-inst-2020-200122)
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia, institutional funding - 200378 (Institute of Information Technology) (RS-MESTD-inst-2020-200378)
- Serbian Academy of Sciences and Arts under project No. F128.
Note:
- Book of abstract:16th International Symposium on Applied Bioinorganic Chemistry (16-ISABC) 11-14th June University of Ioannina Greece
Collections
Institution/Community
Institut za molekularnu genetiku i genetičko inženjerstvoTY - CONF AU - Ašanin P., Darko AU - Vojnović, Sandra AU - Andrejević P., Tina AU - Marković R., Violeta AU - Perdih, Franc AU - Turel, Iztok AU - Djuran I., Miloš AU - Nikodinović-Runić, Jasmina AU - Glišić Đ., Biljana PY - 2023 UR - https://isabc2023.com/ UR - https://imagine.imgge.bg.ac.rs/handle/123456789/1925 AB - Cisplatin is one of the most used anticancer agents, and along with carboplatin and oxaliplatin, is a part of more than 50% of clinically applied anticancer regimens [1]. However, the side effects of cisplatin are severe and include dose-limiting toxicity, such as neurotoxicity, nephrotoxicity and ototoxicity. Platinum(II) complexes with different structure from cisplatin provide many opportunities for design of novel antitumor drugs with improved pharmacological properties. Considering this, in the present study, new platinum(II) complexes with phenothiazine (phtz) and N-methylphenothiazine (N-Mephtz), [PtCl2(phtz)(CH3CN)] (1) and [PtCl2(N-Mephtz)(CH3CN)] (2), were synthesized. These complexes were characterized by elemental microanalysis, NMR (1H and 13C) and IR spectroscopic measurements, while the structure of complex 1 was determined by single-crystal X-ray diffraction analysis. The antitumor activity of the platinum(II) complexes was tested in vitro against a panel of human cancer cell lines, including A549 (lung cancer), A375 (melanoma, skin cancer), MDA-MB-231 (breast cancer), and HCT116 (colon cancer). To check the selectivity of the synthesized complexes 1 and 2, a healthy MRC-5 cell line (lung fibroblasts) was also included in this study. PB - Greece : University of Ioannina C3 - 16th International Symposium on Applied Bioinorganic Chemistry T1 - Structural characterization and antitumor activity of platinum(II) complexes with phenothiazine and N-methylphenothiazine SP - 195 UR - https://hdl.handle.net/21.15107/rcub_imagine_1925 ER -
@conference{ author = "Ašanin P., Darko and Vojnović, Sandra and Andrejević P., Tina and Marković R., Violeta and Perdih, Franc and Turel, Iztok and Djuran I., Miloš and Nikodinović-Runić, Jasmina and Glišić Đ., Biljana", year = "2023", abstract = "Cisplatin is one of the most used anticancer agents, and along with carboplatin and oxaliplatin, is a part of more than 50% of clinically applied anticancer regimens [1]. However, the side effects of cisplatin are severe and include dose-limiting toxicity, such as neurotoxicity, nephrotoxicity and ototoxicity. Platinum(II) complexes with different structure from cisplatin provide many opportunities for design of novel antitumor drugs with improved pharmacological properties. Considering this, in the present study, new platinum(II) complexes with phenothiazine (phtz) and N-methylphenothiazine (N-Mephtz), [PtCl2(phtz)(CH3CN)] (1) and [PtCl2(N-Mephtz)(CH3CN)] (2), were synthesized. These complexes were characterized by elemental microanalysis, NMR (1H and 13C) and IR spectroscopic measurements, while the structure of complex 1 was determined by single-crystal X-ray diffraction analysis. The antitumor activity of the platinum(II) complexes was tested in vitro against a panel of human cancer cell lines, including A549 (lung cancer), A375 (melanoma, skin cancer), MDA-MB-231 (breast cancer), and HCT116 (colon cancer). To check the selectivity of the synthesized complexes 1 and 2, a healthy MRC-5 cell line (lung fibroblasts) was also included in this study.", publisher = "Greece : University of Ioannina", journal = "16th International Symposium on Applied Bioinorganic Chemistry", title = "Structural characterization and antitumor activity of platinum(II) complexes with phenothiazine and N-methylphenothiazine", pages = "195", url = "https://hdl.handle.net/21.15107/rcub_imagine_1925" }
Ašanin P., D., Vojnović, S., Andrejević P., T., Marković R., V., Perdih, F., Turel, I., Djuran I., M., Nikodinović-Runić, J.,& Glišić Đ., B.. (2023). Structural characterization and antitumor activity of platinum(II) complexes with phenothiazine and N-methylphenothiazine. in 16th International Symposium on Applied Bioinorganic Chemistry Greece : University of Ioannina., 195. https://hdl.handle.net/21.15107/rcub_imagine_1925
Ašanin P. D, Vojnović S, Andrejević P. T, Marković R. V, Perdih F, Turel I, Djuran I. M, Nikodinović-Runić J, Glišić Đ. B. Structural characterization and antitumor activity of platinum(II) complexes with phenothiazine and N-methylphenothiazine. in 16th International Symposium on Applied Bioinorganic Chemistry. 2023;:195. https://hdl.handle.net/21.15107/rcub_imagine_1925 .
Ašanin P., Darko, Vojnović, Sandra, Andrejević P., Tina, Marković R., Violeta, Perdih, Franc, Turel, Iztok, Djuran I., Miloš, Nikodinović-Runić, Jasmina, Glišić Đ., Biljana, "Structural characterization and antitumor activity of platinum(II) complexes with phenothiazine and N-methylphenothiazine" in 16th International Symposium on Applied Bioinorganic Chemistry (2023):195, https://hdl.handle.net/21.15107/rcub_imagine_1925 .